JOP20240162A1 - تركيبة صيدلية تتضمن مشتق فثالازينون للإعطاء المشترك مع عقار مضاد للسرطان - Google Patents
تركيبة صيدلية تتضمن مشتق فثالازينون للإعطاء المشترك مع عقار مضاد للسرطانInfo
- Publication number
- JOP20240162A1 JOP20240162A1 JOJO/P/2024/0162A JOP20240162A JOP20240162A1 JO P20240162 A1 JOP20240162 A1 JO P20240162A1 JO P20240162 A JOP20240162 A JO P20240162A JO P20240162 A1 JOP20240162 A1 JO P20240162A1
- Authority
- JO
- Jordan
- Prior art keywords
- administration
- anticancer drug
- formulation containing
- derivative
- phthalassone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263302834P | 2022-01-25 | 2022-01-25 | |
| PCT/IB2023/000030 WO2023144626A1 (en) | 2022-01-25 | 2023-01-25 | Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20240162A1 true JOP20240162A1 (ar) | 2024-07-23 |
Family
ID=87470837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2024/0162A JOP20240162A1 (ar) | 2022-01-25 | 2024-07-23 | تركيبة صيدلية تتضمن مشتق فثالازينون للإعطاء المشترك مع عقار مضاد للسرطان |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250120970A1 (https=) |
| EP (1) | EP4469051A4 (https=) |
| JP (1) | JP2025505381A (https=) |
| KR (1) | KR20240138069A (https=) |
| CN (1) | CN118613264A (https=) |
| AU (1) | AU2023210923A1 (https=) |
| CA (1) | CA3249330A1 (https=) |
| CL (1) | CL2024002218A1 (https=) |
| IL (1) | IL314334A (https=) |
| JO (1) | JOP20240162A1 (https=) |
| MA (1) | MA66598A1 (https=) |
| MX (1) | MX2024009168A (https=) |
| TW (1) | TW202339753A (https=) |
| WO (1) | WO2023144626A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102372706A (zh) * | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| EP2833883A4 (en) * | 2012-04-06 | 2015-12-23 | Indus Pharmaceuticals Inc | NOVEL COMPOSITIONS OF COMBINATIONS OF NONCOVALENT DNA BINDER AND CANCER-INHIBITING AND / OR INFLAMMATORY ACTIVE SUBSTANCES AND THEIR USE IN THE TREATMENT OF ILLNESSES |
| KR101670126B1 (ko) * | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
| US12036222B2 (en) * | 2018-04-04 | 2024-07-16 | The Wistar Institut of Anatomy and Biology | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor |
| JP7626783B2 (ja) * | 2020-04-21 | 2025-02-07 | アイディーエンス カンパニー リミテッド | フタラジノン誘導体及びその中間体を調製するプロセス |
| AU2020444056A1 (en) * | 2020-04-21 | 2022-11-17 | Idience Co., Ltd. | Crystalline forms of phthalazinone compound |
-
2023
- 2023-01-25 EP EP23746538.0A patent/EP4469051A4/en active Pending
- 2023-01-25 CN CN202380018679.4A patent/CN118613264A/zh active Pending
- 2023-01-25 KR KR1020247022669A patent/KR20240138069A/ko active Pending
- 2023-01-25 MA MA66598A patent/MA66598A1/fr unknown
- 2023-01-25 CA CA3249330A patent/CA3249330A1/en active Pending
- 2023-01-25 JP JP2024543458A patent/JP2025505381A/ja active Pending
- 2023-01-25 WO PCT/IB2023/000030 patent/WO2023144626A1/en not_active Ceased
- 2023-01-25 IL IL314334A patent/IL314334A/en unknown
- 2023-01-25 US US18/730,930 patent/US20250120970A1/en active Pending
- 2023-01-25 AU AU2023210923A patent/AU2023210923A1/en active Pending
- 2023-01-25 MX MX2024009168A patent/MX2024009168A/es unknown
- 2023-01-30 TW TW112103190A patent/TW202339753A/zh unknown
-
2024
- 2024-07-23 JO JOJO/P/2024/0162A patent/JOP20240162A1/ar unknown
- 2024-07-23 CL CL2024002218A patent/CL2024002218A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA66598A1 (fr) | 2024-11-29 |
| WO2023144626A1 (en) | 2023-08-03 |
| CN118613264A (zh) | 2024-09-06 |
| EP4469051A4 (en) | 2025-12-17 |
| MX2024009168A (es) | 2024-08-09 |
| IL314334A (en) | 2024-09-01 |
| EP4469051A1 (en) | 2024-12-04 |
| US20250120970A1 (en) | 2025-04-17 |
| JP2025505381A (ja) | 2025-02-26 |
| TW202339753A (zh) | 2023-10-16 |
| KR20240138069A (ko) | 2024-09-20 |
| CL2024002218A1 (es) | 2024-12-20 |
| AU2023210923A1 (en) | 2024-07-25 |
| CA3249330A1 (en) | 2023-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA522441701B1 (ar) | مشتقات كينوكسالين كعقاقير مضادة للسرطان | |
| CY1110495T1 (el) | Χρηση ενος αγωνιστη υποδοχεα nmda για τη θεραπεια εμβοης που προκαλειται απο κοχλιακη διεγερτοτοξικοτητα | |
| BR112018073663A2 (pt) | moduladores de receptores nmda spiro-lactâmicos e seus usos | |
| EA200501203A1 (ru) | Жидкие фармацевтические композиции палоносетрона | |
| MX2024006074A (es) | Inhibidor de parp1 selectivo y aplicacion del mismo. | |
| CO2022005999A2 (es) | Inhibidores del factor d del complemento para administración oral | |
| MX2023005763A (es) | Composiciones y metodos para la administracion dermica profunda de farmacos. | |
| ZA202404070B (en) | Pharmaceutical kit for parenteral co-administration | |
| AR110800A1 (es) | MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA | |
| JOP20240078A1 (ar) | تركيبات إردافيتينيب وأنظمة الإعطاء داخل المثانة | |
| CO2022005926A2 (es) | Inhibidores del factor d del complemento para administración oral | |
| MX2021016093A (es) | Composicion farmaceutica para tratar un tumor. | |
| BR112023025552A2 (pt) | Composições estabilizadas de apilimod e usos das mesmas | |
| MX2020005006A (es) | Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular. | |
| MX2021014830A (es) | Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi. | |
| JOP20240162A1 (ar) | تركيبة صيدلية تتضمن مشتق فثالازينون للإعطاء المشترك مع عقار مضاد للسرطان | |
| MX2024000239A (es) | Medicamentos que comprenden inhibidores de la glicosidasa. | |
| MX2023012483A (es) | Formulaciones farmaceuticas transdermicas para el tratamiento del dolor cronico. | |
| MX384760B (es) | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático. | |
| BR112022026558A2 (pt) | Novo composto e composição farmacêutica para prevenir ou tratar câncer resistente que compreende o mesmo | |
| JOP20220260A1 (ar) | تركيبة صيدلانية تشتمل على مركب مشتق من البنزيميدازول | |
| WO2020036478A3 (es) | Composición farmacéutica sinérgica de aceclofenaco y betametasona para el tratamiento del dolor en las formas localizadas de afecciones reumáticas | |
| AU2021305584A8 (en) | Pharmaceutical composition for preventing or treating cancer comprising naphthoquinone-based compound and immune checkpoint inhibitor as active ingredients | |
| CY1113544T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει ενα συνδυασμο που σχηματιζεται απο τον αντιμικροβιακο παραγοντα σιπροφλοξασινη και τον αντιοξειδωτικο παραγοντα ασκορβικο οξυ για τη θεραπεια λοιμωξεων του ουροποιητικου συστηματος | |
| MX2025010039A (es) | Modulador dual de gen que codifica la enzima beta glucocerebrosidasa (gba1) y glucosilceramida sintasa (gcs) |